Lechleider Robert 4
4 · Immunome Inc. · Filed Jul 27, 2026
Research Summary
AI-generated summary of this filing
Immunome (IMNM) CMO Robert Lechleider Receives 162,000-Unit Award
What Happened
Robert Lechleider, Immunome's Chief Medical Officer, received awards on July 23, 2026 totaling 162,000 units: 54,000 shares represented by restricted stock units (RSUs) and 108,000 derivative securities (award reported as derivative). Both grants show an acquisition price of $0.00 (i.e., no cash was paid). These are compensation awards — not open-market purchases or sales.
Key Details
- Transaction date: 2026-07-23; Form 4 filed 2026-07-27 (filed on the SEC deadline, timely).
- Grant amounts and reported values: 54,000 RSUs @ $0.00 (acquired = $0); 108,000 derivative units @ $0.00 (acquired = $0).
- Shares owned after transaction: not specified in the information provided.
- Footnote F1 (RSUs): Each RSU converts to one share upon settlement; 25% of these RSUs vest and settle annually on each anniversary of the grant date, subject to continued service.
- Footnote F2 (derivative award): 25% of the option-like shares vest on July 23, 2027, then 1/36th of the remaining shares vest monthly thereafter, subject to continued service.
- Transaction code: A = Award/Grant (compensation).
Context
These awards are standard equity compensation signals rather than market trades. The RSUs will convert to shares only as they vest; the derivative award is subject to a typical multi-year vesting schedule and does not represent immediately tradable shares unless vested and exercised/settled. No cash was paid and no sale occurred.
Insider Transaction Report
- Award
Common Stock
[F1]2026-07-23+54,000→ 69,805 total - Award
Employee Stock Option (right to buy)
[F2]2026-07-23+108,000→ 108,000 totalExercise: $22.01Exp: 2036-07-22→ Common Stock (108,000 underlying)
Footnotes (2)
- [F1]Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- [F2]25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.